BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Sobi Secures Positive CHMP Opinion For Aspaveli In Rare Kidney Diseases

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-...

December 30, 2025 | News

Mabwell Secures US FDA IND Clearance For Anti ST2 Antibody In COPD

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...

December 26, 2025 | News

BrioHealth Solutions Reaches 100th Patient Enrollment In INNOVATE LVAD Trial

BrioHealth Solutions announces it has reached a major milestone with the 100th enrollment in the INNOVATE Trial of the BrioVAD® System, a Lef...

December 26, 2025 | News

Galaxy Therapeutics Completes Enrollment In Landmark U.S. IDE Trial For Brain Aneurysm Device

Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, announced it has successfully completed e...

December 26, 2025 | News

SN Bioscience Secures US FDA Orphan Drug Designation For SNB 101 In Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (incl...

December 25, 2025 | News

Mondego Bio Selects ZE00 0388 As Lead Clinical Candidate And Prepares For Phase One Entry In 2026

Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selecti...

December 25, 2025 | News

Promontory Therapeutics Exceeds Interim Efficacy Bar In Thymoma Study With PT 112

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two re...

December 24, 2025 | News

NeuroSense Reports Clean Safety Profile From Phase 2 PrimeC Study In Alzheimer’s Disease

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for&nbs...

December 24, 2025 | News

GC Biopharma Secures MFDS Approval For Phase 1 Trial Of mRNA Covid 19 Vaccine Candidate

Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform GC Biopharma (...

December 24, 2025 | News

Japan Approves Incyte’s Zynyz As First Line Treatment For Advanced Anal Canal Cancer

Incyte Biosciences Japan G.K. announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination w...

December 23, 2025 | News

Merck Secures World First Regulatory Approval For Pimicotinib In Rare Joint Tumour TGCT In China

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantl...

December 23, 2025 | News

Qihan Biotech Initiates Phase I IIa Dosing Of Allogeneic CAR T Therapy For Refractory Lupus

Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-...

December 22, 2025 | News

PeptiDream Advances Oral Dual IL17 Inhibitor Into Clinical Development Portfolio

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”)(Tokyo: 4587) a...

December 19, 2025 | News

Stay Connected